Rigel Pharmaceuticals Reports Promising Phase 1b Study Results

Rigel ( (RIGL) ) has provided an announcement.

On December 7, 2025, Rigel Pharmaceuticals announced updated data from its ongoing Phase 1b study of R289, an oral prodrug, in patients with relapsed or refractory lower-risk myelodysplastic syndrome (MDS). The study, presented at the 67th ASH Annual Meeting, showed that R289 was generally well tolerated and demonstrated preliminary efficacy, with 33% of evaluable transfusion-dependent patients achieving red blood cell transfusion independence. These results underscore the potential of R289 as a treatment option for lower-risk MDS patients, with further clinical trials anticipated in the second half of 2026.

The most recent analyst rating on (RIGL) stock is a Buy with a $57.00 price target. To see the full list of analyst forecasts on Rigel stock, see the RIGL Stock Forecast page.

Spark’s Take on RIGL Stock

According to Spark, TipRanks’ AI Analyst, RIGL is a Outperform.

Rigel Pharmaceuticals scores highly due to its strong financial performance and positive earnings call, which highlighted significant revenue growth and strategic advancements. Technical indicators also support a bullish outlook, while valuation metrics suggest the stock is undervalued. The termination of a CNS program is a minor concern but does not significantly impact the overall positive sentiment.

To see Spark’s full report on RIGL stock, click here.

More about Rigel

Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and providing novel therapies for hematologic disorders and cancer. Founded in 1996 and based in South San Francisco, California, Rigel is a commercial stage company with a pipeline of potential products.

Average Trading Volume: 635,334

Technical Sentiment Signal: Strong Buy

Current Market Cap: $787.8M

See more insights into RIGL stock on TipRanks’ Stock Analysis page.